Next Article in Journal
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development
Next Article in Special Issue
EBNA1 IgM-Based Discrimination Between Rheumatoid Arthritis Patients, Systemic Lupus Erythematosus Patients and Healthy Controls
Previous Article in Journal
Targeting the MHC Ligandome by Use of TCR-Like Antibodies
Previous Article in Special Issue
The Diagnostic and Clinical Utility of Autoantibodies in Systemic Vasculitis
Open AccessReview

Ion Channel Targeting with Antibodies and Antibody Fragments for Cancer Diagnosis

Department of Experimental and Clinical Medicine, Section of Internal Medicine, University of Florence, 50134 Firenze, Italy
*
Author to whom correspondence should be addressed.
Antibodies 2019, 8(2), 33; https://doi.org/10.3390/antib8020033
Received: 21 March 2019 / Revised: 17 May 2019 / Accepted: 20 May 2019 / Published: 24 May 2019
(This article belongs to the Special Issue Antibody-Based Diagnostics)
The antibody era has greatly impacted cancer management in recent decades. Indeed, antibodies are currently applied for both cancer diagnosis and therapy. For example, monoclonal antibodies are the main constituents of several in vitro diagnostics, which are applied at many levels of cancer diagnosis. Moreover, the great improvement provided by in vivo imaging, especially for early-stage cancer diagnosis, has traced the path for the development of a complete new class of antibodies, i.e., engineered antibody fragments. The latter embody the optimal characteristics (e.g., low renal retention, rapid clearance, and small size) which make them ideal for in vivo applications. Furthermore, the present review focuses on reviewing the main applications of antibodies and antibody fragments for solid cancer diagnosis, both in vitro and in vivo. Furthermore, we review the scientific evidence showing that ion channels represent an almost unexplored class of ideal targets for both in vitro and in vivo diagnostic purposes. In particular, we review the applications, in solid cancers, of monoclonal antibodies and engineered antibody fragments targeting the voltage-dependent ion channel Kv 11.1, also known as hERG1. View Full-Text
Keywords: antibodies; cancer diagnostics; in vivo imaging; engineered antibody fragments; hERG1 antibodies; cancer diagnostics; in vivo imaging; engineered antibody fragments; hERG1
Show Figures

Figure 1

MDPI and ACS Style

Duranti, C.; Arcangeli, A. Ion Channel Targeting with Antibodies and Antibody Fragments for Cancer Diagnosis. Antibodies 2019, 8, 33.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop